基于伊米达的zwitterionic液体修饰的PEG-PLGA纳米颗粒作为潜在的静脉药物输送载体
Gaya S Dasanayake1, Christine M Hamadani1, Gagandeep Singh1
1Department of Chemistry and Biochemistry, University of Mississippi, University, MS 38677, USA. eetanner@olemiss.edu.
Nanoscale
|February 27, 2024
概括
涂有基于Zwitterionic imidazole的离子液 (ZIL) 的纳米颗粒显示了对癌细胞和红细胞的增强向. 这种新的平台可以提高癌症治疗的药物输送效率.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 兹维特里离子材料为纳米粒子 (NP) 药物递送系统提供了先进的性能.
- 功能化的zwitterions增强生物相容性,生物识别和防物质.
- 这些特征对于有效的生物向和治疗疗效至关重要.
研究的目的:
- 开发和描述基于zwitterionic imidazole的离子液 (ZIL) 涂层的新型纳米粒子.
- 评估ZIL-NP在改善药物输送,特别是癌症治疗方面的潜力.
- 研究ZIL-NP与红细胞和癌细胞等生物成分的相互作用.
主要方法:
- 超声波纳米沉被用于制造涂有ZIL.的PEG-PLGA纳米颗粒.
- 描述包括测量水力动力半径和表面电荷.
- 核磁共振 (NMR) 光谱被用来确认ZIL组装.
- 在体外研究中评估了癌症细胞系中的血红相容性 (血解) 和细胞吸收.
主要成果:
- ZIL涂层增加了纳米粒子的水力动力半径,并将表面电荷转向中性.
- 纳米粒子上的ZIL组装由ZIL结构控制,涉及非共价相互作用.
- ZIL-NP对红细胞具有选择性亲和力,人体血液溶解率低 (<5%).
- 与未经修改的NP相比,在人类三阴性乳腺癌细胞 (MDA-MB-231) 中观察到ZIL-NP的增强积累.
- 蛋白质组分析显示,小鼠和人血清之间的蛋白质吸附有差异.
结论:
- 结构调整的ZIL涂层纳米颗粒代表了药物输送的有希望的平台.
- 这些ZIL-NP显示了针对红细胞和癌细胞的增强向的潜力.
- 这些发现支持ZIL-NP的开发,通过增强的药物输送系统来改善癌症治疗方法.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
358
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
358
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
174
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
174
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
211
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
211